• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Fate Therapeutics (NQ: FATE )

    3.670 +0.080 (+2.23%)
    Streaming Delayed Price Updated: 9:46 AM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 187,584
    Open 3.650
    Bid (Size) 3.670 (4)
    Ask (Size) 3.680 (2)
    Prev. Close 3.590
    Today's Range 3.620 - 3.695
    52wk Range 1.630 - 8.830
    Shares Outstanding 98,384,456
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
    Via Benzinga
    This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
    Via Benzinga

    Performance

    YTD
    -0.54%
    -0.54%
    1 Month
    -0.81%
    -0.81%
    3 Month
    -50.61%
    -50.61%
    6 Month
    +9.55%
    +9.55%
    1 Year
    -36.61%
    -36.61%

    More News

    Read More
    Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
    Via Benzinga
    Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Where Fate Therapeutics Stands With Analysts
    Via Benzinga
    Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
    Via Benzinga
    Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Recap: Fate Therapeutics Q4 Earnings
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Fate Therapeutics to Present at Upcoming March Investor Conferences
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
    From Fate Therapeutics, Inc.
    Via GlobeNewswire
    Earnings Scheduled For February 26, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.